エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 7, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 7, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| United-Guardian, Inc. | ||
| Date: August 7, 2026 | By: | /s/ Donna Vigilante |
| Donna Vigilante | ||
| President | ||
EXHIBIT 99.1
United-Guardian Reports Second Quarter Results
HAUPPAUGE, N.Y., Aug. 07, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2026. Second quarter net sales increased by 10% from $2,838,225 in 2025 to $3,108,267 in 2026, with net income increasing 16% from $626,826 ($0.14 per share) to $728,579 ($0.16 per share). Net sales for the six-month period ended June 30th increased by 12% from $5,319,352 in 2025 to $5,980,489 in 2026, and net income increased by 30% from $1,187,721 ($0.26 per share) to $1,547,481 ($0.34 per share).
Donna Vigilante, President of United-Guardian, stated, “I am pleased to report that sales and earnings increased in both the second quarter and first half of 2026. Sales of our cosmetic ingredients and pharmaceutical products increased during both periods compared with the same periods in 2025. Cosmetic ingredient sales increased by 44% in the second quarter and 34% in the first half of 2026 compared with the same periods in 2025. The growth in cosmetic ingredient sales was primarily attributable to increased purchases by Ashland Specialty Ingredients (“ASI”), our largest cosmetic distributor. ASI had experienced higher-than-normal inventory levels in 2025, which have since been reduced, resulting in the resumption of regular purchasing levels in the first half of 2026. Pharmaceutical sales increased by 1% in the second quarter and 11% in the first half of 2026 compared with the same periods in 2025, with Renacidin®, our most important pharmaceutical product, serving as the primary driver of growth.”
“As we move through 2026, we remain focused on our growth plan, which includes expanding promotional efforts and increasing market awareness for Renacidin, particularly among physicians and care providers; increasing awareness of our “natural” products; and growing our medical lubricant business.”
United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
| Contact: | Donna Vigilante |
| (631) 273-0900 | |
| dvigilante@u-g.com |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| Financial Results for the Three and Six Months Ended June 30, 2026 and 2025 | ||||||||||||
| STATEMENTS OF INCOME (unaudited) | ||||||||||||
|
THREE MONTHS ENDED JUNE 30, |
SIX MONTHS ENDED JUNE 30, |
|||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Net sales | $ | 3,108,267 | $ | 2,838,225 | $ | 5,980,489 | $ | 5,319,352 | ||||
| Costs and expenses: | ||||||||||||
| Cost of sales | 1,562,465 | 1,340,854 | 3,010,254 | 2,463,930 | ||||||||
| Operating expenses | 667,282 | 694,050 | 1,334,245 | 1,326,785 | ||||||||
| Research and development expense |
124,395 | 107,868 | 239,416 | 222,262 | ||||||||
| Total costs and expenses | 2,354,142 | 2,142,772 | 4,583,915 | 4,012,977 | ||||||||
| Income from operations | 754,125 | 695,453 | 1,396,574 | 1,306,375 | ||||||||
| Other income: | ||||||||||||
| Investment income | 70,445 | 70,573 | 140,259 | 155,260 | ||||||||
| Net gain on marketable securities |
48,365 | 24,576 | 66,107 | 36,926 | ||||||||
| Settlement income | 36,360 | --- | 339,493 | --- | ||||||||
| Gain on sale of asset | 8,310 | --- | 8,310 | --- | ||||||||
| Total other income | 163,480 | 95,149 | 554,169 | 192,186 | ||||||||
|
Income before provision for income taxes |
917,605 | 790,602 | 1,950,743 | 1,498,561 | ||||||||
| Provision for income taxes | 189,026 | 163,776 | 403,262 | 310,840 | ||||||||
| Net income | $ | 728,579 | $ | 626,826 | $ | 1,547,481 | $ | 1,187,721 | ||||
|
Earnings per common share (basic and diluted) |
$ | 0.16 | $ | 0.14 | $ | 0.34 | $ | 0.26 | ||||
|
Weighted average shares (basic and diluted) |
4,594,319 | 4,594,319 |
4,594,319 |
4,594,319 |
||||||||